1 # Title
2
3 *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke
4
5 # Authors
6

Juan L. Rodriguez-Flores[1], Shareef Khalid[2], Neelroop Parikshak[1], Asif Rasheed[3], Bin Ye[1],
Manav Kapoor[1], Joshua Backman[1], Farshid Sepehrband[1], Silvio Alessandro DiGioia[4], Sahar
Gelfman[1], Tanima De[1], Nilanjana Banerjee[1], Deepika Sharma[1], Hector Martinez[4], Sofia
Castaneda[5], David D'Ambrosio[4], Xingmin A. Zhang[1], Pengcheng Xun[4], Ellen Tsai[6], I-Chun
Tsai[4], Regeneron Genetics Center[1], Maleeha Zaman Khan[3], Muhammad Jahanzaib[3],
Muhammad Rehan Mian[3], Muhammad Bilal Liaqat[3], Khalid Mahmood[7], Tanvir Us Salam[8],
Muhammad Hussain[8], Javed Iqbal[10], Faizan Aslam[11], Michael N. Cantor[1], Gannie Tzoneva[1],
John Overton[1], Jonathan Marchini[1], Jeff Reid[1], Aris Baras[1], Niek Verweij[1], Luca A. Lotta[1],
Giovanni Coppola[1], Katia Karalis[1], Aris Economides[1], Sergio Fazio[4], Wolfgang Liedtke[4],
John Danesh[12], Ayeesha Kamal[9], Philippe Frossard[3], Thomas Coleman[1], Alan R. Shuldiner[1],
Danish Saleheen[2,3]
18
19 # Affiliations
20
[1.] Regeneron Genetics Center, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA
[2.] Columbia University, New York, NY, USA
[3.] Center for Non-Communicable Diseases, Karachi, Pakistan
[4.] Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA
[5.] Rye Country Day School, Rye, NY, USA
[6.] University of California at Los Angeles, Los Angeles, CA, USA
[7.] Dow University of Health Sciences and Civil Hospital, Karachi, Pakistan
[8.] Lahore General Hospital, Lahore, Pakistan
[9.] Section of Neurology, Department of Medicine, Aga Khan University, Karachi, Pakistan
[10.] Department of Neurology, Allied Hospital, Faisalabad, Pakistan.
[11.] Department of Neurology, Aziz Fatima Hospital, Faisalabad, Pakistan.
[12.] Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
.
34
35 # Correspondence
36
37 Danish Saleheen, danish.saleheen@cncdpk.com
38 Alan Shuldiner, alan.shuldiner@regeneron.com
39

1   **Abstract**
2

The genetic factors of stroke in South Asians are largely unexplored. Exome-wide sequencing
and association analysis (ExWAS) in 75 K Pakistanis identified
NM_000435.3(NOTCH3):c.3691C>T, encoding the missense amino acid substitution
p.Arg1231Cys, enriched in South Asians (alternate allele frequency = 0.58% compared to
0.019% in Western Europeans), and associated with subcortical hemorrhagic stroke [odds ratio
(OR) = 3.39, 95% confidence interval (CI) = [2.26, 5.10], p value = 3.87×10^{-9}), and all strokes
(OR [CI] = 2.30 [3.01, 1.77], p value = 7.79×10^{-10}). *NOTCH3* p.Arg231Cys was strongly
associated with white matter hyperintensity on MRI in United Kingdom Biobank (UKB)
participants (effect [95% CI] in SD units = 1.1 [0.61, 1.5], p value = 3.0×10^{-6}). The variant is
attributable for approximately 5.5% of hemorrhagic strokes and 1% of all strokes in South
Asians. These findings highlight the value of diversity in genetic studies and have major
implications for genomic medicine and therapeutic development in South Asian populations.

Introduction

Pakistan, a country in South Asia, comprises over 231 million inhabitants. It is the fifth most populous country in the world with diverse ancestral backgrounds from South and Central Asia, West Asia, and Africa. Pakistan, and in general South Asia, represents an understudied region in large-scale genetic studies [1], thus providing an opportunity for novel discoveries of the genetic basis of diseases.

Stroke is a leading cause of death globally [2], and epidemiological studies suggest an elevated incidence and prevalence of stroke in Pakistan [2, 3] relative to Europe. The disparities in incidence and prevalence between Pakistan and Europe could be due to many factors, including difference in access to healthcare facilities with high-quality diagnostic capabilities and public health awareness and education. These disparities also may reflect differences in prevalence of risk factors such as hypertension and diabetes, lifestyle factors such as diet, physical activity and smoking, and genetic predispositions [4-7] . Studies of the genetic underpinnings of stroke in Pakistani populations have been limited, making this understudied population an opportune venue for stroke exome-wide sequencing and association studies (ExWAS).

At least 9 rare monogenic disorders are characterized by increased stroke risk, such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) due to mutations in *NOTCH3* [8]. CADASIL is distinct from other hereditary stroke diseases because it is characterized by vascular smooth muscle cell (VSMC) degeneration in small arteries and accumulation of protein aggregates known as granular osmophilic material (GOM) that contain aggregates of misfolded *NOTCH3* extracellular domain (ECD). The more common forms of stroke are likely polygenic with substantial contributions from behavioral and environmental factors as well as age. Major risk factors include high systolic blood pressure, high body mass index, hyperlipidemia, elevated glucose, and smoking [9]. Recent genome-wide association studies (GWAS) identified single nucleotide variants (SNVs) in more than 28 loci associated with stroke [10]. These variants are common non-coding variants with small effect sizes and were identified in predominantly European ancestry populations.

The aim of this study was to identify protein coding deleterious missense or loss-of-function (LoF) variants associated with stroke phenotypes in the Pakistani population. We performed exome sequencing in a 31 K discovery cohort consisting of 5,135 stroke cases and 26,602 controls of Pakistani origin. ExWAS identified NM_000435.3(NOTCH3):c.3691C>T, encoding the missense amino acid substitution p.Arg1231Cys, with an approximately three-fold increased risk of hemorrhagic stroke in heterozygotes. Follow-up meta-analysis of 61 K Pakistani (including an additional 160 cases and 30,239 controls) provided further support for association of *NOTCH3* p.Arg1231Cys with stroke (combined ischemic and hemorrhagic). This variant was present in approximately 1% of Pakistani and was markedly enriched with respect to Europeans in multiple South Asian (SAS) and West Asian (WAS) (also referred to as Greater Middle Eastern [11]) populations ranging from Turkey to India. The variant was estimated to explain up to 1% of strokes and 5% of hemorrhagic strokes in South Asia, a region having a population of > 2 billion people, thus having significant medical implications in these very large yet understudied populations and their global diaspora.

1
2
3
4   **Results**
5
6   **ExWAS in the Pakistan Genomics Resource (PGR) discovery cohort identifies a markedly**
7   **enriched missense variant in *NOTCH3* associated with stroke**
8
Characteristics of the 5,135 stroke cases and 26,602 controls in the discovery cohort are
summarized in **Table 1**. Compared to controls, stroke cases were modestly older and had a
higher prevalence of known risk factors for vascular disease including hypertension, diabetes,
myocardial infarction, and tobacco use (all p < 0.01). As expected, in this cohort ascertained for
stroke, most cases were ischemic strokes and most hemorrhagic strokes were subcortical
(**Supplementary Figures 1 and 2, Supplementary Table 1**).
15
Case:control ExWAS for all stroke cases and 4 stroke subtypes with sufficient case counts to
provide statistical power (**Supplementary Table 1**) identified a genome-wide significant (p
value < 5.0×10^{-8}) association for NM_000435.3(NOTCH3):c.3691C>T (rs201680145), encoding
the missense amino acid substitution p.Arg1231Cys, with subcortical hemorrhagic stroke (OR
[95% CI] = 3.39 [2.26, 5.1], p value = 3.87×10^{-9}; AAF = 0.58%) (**Figure 1B, Supplementary**
Table 1 and Supplementary Figures 3 and, 4). The p.Arg1231Cys variant also showed
evidence for association with all strokes combined (OR [95% CI] = 2.18 [1.65, 2.89], p value =
4.44×10^{-8}) and other sub-categories of stroke (**Supplementary Table 2**). No other variants in the
locus were associated with stroke (**Figure 1C**). We did not observe an association between
p.Arg1231Cys and history of hypertension, elevated systolic or diastolic blood pressure, or
smoking, known major risk factors for stroke (**Supplementary Tables 3 and 4**), and inclusion of
these risk factors in regression analysis did not appreciably alter the effect of p.Arg1231Cys on
stroke risk (**Supplementary Table 5**).
29
NOTCH3 encodes Notch Receptor 3, a transmembrane signaling protein and part of an
evolutionarily conserved family that plays a pleiotropic role in cell-cell interaction and neural
development [12]. The extra-cellular domain (ECD) of *NOTCH3* consists of 34 Epidermal
Growth Factor-like repeat (EGFr) domains [13], each containing 6 Cysteine (Cys) residues that
form three disulfide bonds (**Figure 2**). Adding or removing Cys residues in the first 6 EGFr
domains cause classical CADASIL, a highly penetrant rare autosomal dominant disease
clinically characterized by migraine with aura, early-onset recurrent strokes, dementia, and
behavioral changes [8]. The Cys-altering variant associated with stroke in this study,
p.Arg1231Cys, occurs in the 31st EGFr [14] and is predicted deleterious (**Supplementary Table**
6). Stroke cases heterozygous for p.Arg1231Cys and stroke cases without the variant were
similar with respect to age, age of stroke onset, type of stroke, and stroke risk factors, suggesting
a milder form of CADASIL not obviously clinically distinguishable from common forms of
stroke in this population, although a detailed history for migraine or other manifestations of
CADASIL were not available (**Table 1**).
44
45   **Replication and Meta Analysis in PGR**
46

An additional 44 K Pakistani were recruited and whole-exome sequenced by the Broad Institute,
approximately 30 K of whom self-reported stroke case:control status was obtained (160 cases
and 30,239 controls. Replication of the association was observed in this independent cohort (OR
[95% CI] = 3.49 [1.56, 7.83], p value = 5.00×10^{-3}. Meta-analysis for all strokes in the combined
61 K cohort achieved a genome-wide significant p value (OR [95% CI]) = 2.30 [1.76, 2.99], p
value = 7.08×10^{-10}) (**Figure 3**).
7
8 **Recall by Genotype**
9
10 A total of 12 p.Arg1231Cys homozygotes from 9 nuclear families were identified in the PGR,
11 including 9 discovery cohort probands and 3 follow-up cohort relatives identified through a
12 callback of 128 call-back participants. Baseline characteristics of the 12 homozygotes are shown
13 in **Supplementary Table 7**. Three of twelve (25%) homozygotes had a history of stroke; of note,
14 all with stroke were >65 years of age while all without a history of stroke were <55 years of age.
15
Eight out of twelve (66%) p.Arg1231Cys homozygotes had a history of hypertension. Among
the 128 callback participants, both systolic and diastolic blood pressure were trending higher
(**Supplementary Table 8**). While there was no association with hypertension in the discovery
cohort, p.Arg1231Cys homozygotes in the PGR had nominally higher diastolic blood pressure
than heterozygotes or homozygous reference individuals (median = 95 mmHg, interquartile
range 86 to 100; heterozygotes (median = 80 mmHg, interquartile range = 80 to 90), p value =
0.016 (**Supplementary Table 9**).
23
24 **Allele Frequency and Population Attributable Risk**
25
The allele frequency of p.Arg1231Cys was 1.1% across the PGR 75 K, equivalent to a
population prevalence of 1 in 46. After removing cases recruited for cardiovascular diseases
(individuals enrolled at time of acute stroke, MI, and heart failure), the allele frequency of the
variant was 0.51%, equivalent to a population prevalence of 1 in 98. This frequency was orders
of magnitude higher relative to exomes of European ancestry from UK Biobank (AAF =
0.019%), corresponding to a population prevalence of 1 in 2,614). The variant was enriched
(AAF > 0.1%) in other South Asian and West Asian populations [15] both within and outside of
Pakistan (**Supplementary Data, Supplementary Tables 10 and 11, Supplementary Figure 5**).
34
35 We estimate that 5.5% [bootstrap 95% CI based on 10,000 resamples: 4.2% to 6.7%] of
36 hemorrhagic strokes and 1.0% [bootstrap 95% CI based on 10,000 resamples: 0.6% to 1.4%] of
37 all strokes in the Pakistani population are attributable to p.Arg1231Cys. Thus, this variant is a
38 common cause of strokes in SAS and WAS populations, a finding that has implications for
39 medical care as well as global health in these populations.
40
41 **Suggestive Associations at Other Loci**
42
43 Although *NOTCH3* p.Arg1231Cys was the only variant associated with stroke at a genome-wide
44 significant p value below 5.0×10^{-8}, there were a total of 9 associations (5 loci) with p values
45 below 1.0×10^{-6} and at least 10 variant carriers (**Supplementary Table 12**). In addition to

1 *NOTCH3*, these included one known locus previously associated with stroke in a recent GWAS,
2 lymphocyte specific protein *LSP1* [10].
3
The *LSP1* locus variant with suggestive association with intracerebral hemorrhagic stroke in this
study was a common intronic variant (rs661348, OR [95% CI] = 1.3 [1.2, 1.4], p value = 8.0×10^{-8}
, AAF = 0.27). While rs661348 was not previously associated with stroke, two common non-
coding variants in the *LSP1* locus were previously reported to be associated with stroke
(rs569550 and rs1973765) [10]. Both variants were in linkage disequilibrium with rs661348 ($r^2 >$
0.4 in 10 K unrelated PGR participants). A test of association for rs661348 conditional on these
variants reduced the strength of the association for rs661348 to nominal (8.83×10^{-4})
(**Supplementary Table 17**), suggesting that rs661348 represents the same known stroke risk
locus. The *LSP1* locus was previously reported to be associated with hypertension [16]. In
PGR there was a weak association with hypertension (p value = 2.61×10^{-2}) (**Supplementary**
Tables 13, 14, 15, and 16).
15
16 **NOTCH3 p.Arg1231Cys is associated with stroke and CADASIL-like phenotypes in UK**
17 **Biobank**
18
To investigate stroke and CADASIL-related phenotypes in an independent cohort, UK Biobank
data was reviewed for associations with *NOTCH3* p.Arg1231Cys. A total of 255 heterozygotes
for *NOTCH3* p.Arg1231Cys were observed in 450 K exome-sequenced individuals from this
predominantly European cohort, with a markedly lower allele frequency (AAF = 0.019%)
(**Supplementary Table 18**). Phenome-wide association (PheWAS) of 10,168 phenotypes
revealed nominally significant association of p.Arg1231Cys with ischemic stroke (OR [95%CI]
= 4.0 [1.9, 8.6]), p value = 4.1×10^{-4}), all strokes combined (OR [95% CI] = 1.9 [1.1, 3.5], p value
= 0.031), hypertension (ICD 10 code I10) (OR [95% CI] = 1.5 [1.1, 2.2], p value = 0.019), and
recurrent major depression (OR [95% CI] = 3.2 [1.5, 6.8], p value = 0.0031) (**Supplementary**
Table 19). No association was observed for hemorrhagic stroke, migraine, dementia, mood
changes, Alzheimer's disease, or urinary incontinence. The lack of association (p value = 0.066)
with hemorrhagic stroke in UKB Europeans was likely due to low statistical power, given the
lower variant allele frequency and lower hemorrhagic stroke prevalence in UKB compared to
PGR. Nonetheless, the odds ratio (OR [95% CI] = 5.8 [0.88, 39.1]) was high.
33
In addition to recurrent strokes, brain white matter loss is a major and early phenotype
characteristic of CADASIL that is focused on particular brain regions [8, 14]. *NOTCH3*
p.Arg1231Cys was strongly associated with a cluster of brain MRI quantitative phenotypes, e.g.,
total volume of white matter hyperintensities (WMH) from T1 and T2 FLAIR images (effect
[95% CI] in SD units = 1.1 [0.61, 1.5], p value = 3.0×10^{-6}) with carriers having 7.4 cm^3 more
WMH volume than controls (**Supplementary Figure 6** and **Supplementary Table 20**). The
most prominent alterations in WMH in p.Arg1231Cys carriers were observed in the centrum
semiovale and periventricular white matter (**Supplementary Figure 7**). Taken together, these
results demonstrate *NOTCH3* p.Arg1231Cys carriers have increased risk of established markers
of small vessel disease and clinical phenotypes observed in CADASIL [8].
44
45 **Pathogenic burden of all Cys-altering variants within NOTCH3 EGFr domains specifically**
46 **associated with CADASIL phenotypes in UK Biobank**

1
Burden test analysis allows for increased statistical power to detect association by combining
signal across multiple rare variants. Prior studies have shown that pathogenic variants in
CADASIL are limited to variants that add or remove a Cysteine (Cys-altering) in *NOTCH3* EGFr
domains normally containing 6 Cysteines. Furthermore, patients with Cys-altering variants in the
first 6 EGFr domains have more severe symptoms than in EGFr domains 7 to 34 [14, 17, 18],
including larger regions of brain white matter loss [19], more granular osmophilic material
(GOM) aggregates in blood vessels [19], and worse prognosis [14].
9
In order to test these hypotheses, a set of custom gene burden tests were designed and compared
to single variant test results for *NOTCH3* p.Arg1231Cys. In UKB, 758 individuals carried one of
98 unique Cys-altering variants across the 34 EGFr domains in *NOTCH3* (**Supplementary
Tables 21 and 22**). A burden test aggregating all UKB EGFr domain Cys-altering variants into
a single statistical test was strongly associated with stroke (OR [95% CI] = 2.86 [2.14, 3.82], p
value = 6.29×10^{-10}; AAF = 0.01%) (**Table 2**). In contrast to Cys-altering variants within EGFr
domains, Cys-altering variants outside of EGFr domains were not associated with stroke (OR
[95% CI] = 0.97 [0.46, 2.03], p value = 9.3×10^{-1}; AAF =0.039%) (**Table 2**). In order to rule out
the possibility that any missense variants in EGFr domains are associated with stroke, a test
limited to the most commonly altered (added or removed) amino acid in *NOTCH3*, serine (Ser),
was tested and did not show any evidence of association with stroke (OR [95% CI] = 0.98 [(0.8,
1.2], p value = 0.084; AAF = 0.54%] (**Table 2**, **Supplementary Table 23**). Interestingly, a
burden test limited only to predicted loss of function (pLoF) variants (frameshift, splice variant,
stop gain) did not show significant evidence for association with stroke (OR [95% CI] = 1.38
[0.50, 3.85], p value = 0.54; AAF = 0.019%) (**Table 2, Supplementary Table 24**). These results
provide evidence to support the hypothesis that EGFr domain Cys-altering variants within
NOTCH3 are associated with stroke, in contrast to other protein-altering variants.
27
28   While hemorrhagic stroke represents a small proportion of the strokes reported in the UKB, the
29   set of Cys-altering variants were also tested for association with hemorrhagic stroke. A nominal
30   association with hemorrhagic stroke (OR [95% CI] = 3.61 [1.39, 9.34], p value = 8.31×10^{-3}; AAF
31   0.025%) was observed, despite low statistical power.
32
Consistent with stroke risk, in MRI data of 35,344 UKB individuals, Cys-altering variants in
NOTCH3 EGFr domains were strongly associated with WMH volume (p value = 3.7×10^{-13}; with
carriers having 5.4 cm^3 greater WMH volume than controls). These WMH differences were
strongest in the centrum semiovale and periventricular white matter (**Supplementary Figure 7**).
Additionally, we found strong WMH signal in the external capsule, which is known to be
involved in CADASIL. We found weaker evidence for association of *NOTCH3* LoF variants
with WMH (effect size [95% CI] = 6.8 cm^3 [4.2 cm^3, 10.9 cm^3], p-value = 1.68×10^{-4}).
40
Prior studies have binned *NOTCH3* EGFr domain Cys-altering variants in up to three distinct
severity or risk groups based on EGFr domain number [10, 14, 17]. Indeed, we observed a much
larger effect size for Cys-altering variants in high-risk EGFr domains 1-6 (OR [95% CI] = 29.5
[10.4, 83.8], p value = 1.37×10^{-7}; AAF = 0.002%] compared to Cys-altering variants in EGFr
domains 7-34 (OR [95% CI] = 2.55 [1.87, 3.46], p value = 1.59×10^{-7}; AAF = 0.098%) (**Table 2,
Supplementary Table 23**). These results are consistent with prior reports of differences in

stroke risk between EGFr domain risk groups not correlated with differences in signaling activity
between EGFr risk groups [17].
3
4 **Discussion**
5
This report describes the largest ExWAS of stroke conducted thus far in a South Asian
population and highlights a Cys-altering missense variant in the 31st EGFr domain of *NOTCH3*
associated with stroke at a genome-wide level of statistical significance. This is the first study to
report a genome-wide-significant association between *NOTCH3* and stroke, a discovery enabled
because *NOTCH3* p.Arg1231Cys is markedly enriched in Pakistanis compared to Western
European and non-Eurasian populations. Harbored in ~1 percent of Pakistani, p.Arg1231Cys is
associated with a ~3-fold increased risk of hemorrhagic stroke. While some regional variability
in the allele frequency is observed, p.Arg1231Cys is enriched in populations ranging from
Turkey in West Asia to India in South Asia, suggesting a substantial contribution to stroke risk in
millions of individuals across South Asia and West Asia as well as their global diaspora.
16
NOTCH3 was not previously associated with stroke in the largest GWAS predominantly
consisting of European-derived participants [10]. In contrast to prior studies, both the discovery
and replication cohorts in this study were South Asian, hence avoiding the bias encountered in
studies with a European discovery cohort. Given the much lower allele frequency of
p.Arg1231Cys in European populations, we observed a nominal association between
p.Arg1231Cys and stroke in the UK Biobank study, showing a similar effect size as in South
Asians. Nominal associations were also observed for phenotypes related to CADASIL, such as
hypertension and depression. While brain images were not available for the Pakistani cohort, a
strong association was observed between p.Arg1231Cys and quantitative brain MRI phenotypes
in UKB data, such as white matter hyperintensity.
27
Cys-altering mutations in proximal EGFr domains of *NOTCH3* are known to cause autosomal
dominant CADASIL, a rare highly penetrant distinct syndrome that includes early onset
recurrent subcortical strokes. In contrast to classical CADASIL pathogenic variants,
p.Arg1231Cys is in the 31st of 34 EGFr domains, appears to have more moderate penetrance, and
is not obviously clinically distinguishable from more common multi-factorial forms of stroke in
South Asians. The p.Arg1231Cys *NOTCH3* variant is currently classified in ClinVar and recent
reviews [14] as a variant of uncertain significance [20] or "low risk" [17]; however, based on our
current findings, there is strong genetic, computational, and imaging evidence of pathogenicity
for this variant despite reduced penetrance and severity compared to "classic" Cys-altering
CADASIL pathogenic variants in EGFr domains 1 to 6 [14, 19].
38
Prior studies have debated if the mechanism whereby Cys-altering variants contribute to
CADASIL-related pathology is through toxic aggregate gain of function (GoF) or a loss of
normal signaling function (LoF). One study demonstrated excess risk of CADASIL-related
phenotypes for Cys-altering variants in EGFr domains 1 to 34 [18], while other studies showed
greater risk in EGFr domains 1 to 6 relative to EGFr domains 7 to 34 [14, 19]. A recent study
showed evidence for expanding the high-risk tier of EGFr domains to include domains 8, 11, and
26 [17]. The current study provides three additional refinements. First, this study is the first to
assess risk for LoF variants, and did not observe significant association signal (**Table 2**),

although the number of LoF carriers was small and thus power is limited to detect such
associations. These findings suggest that pathological mechanisms driven by dysfunctional
disulfide bridge formation and subsequent protein misfolding and aggregation, as is commonly
observed in CADASIL, may be more pathologic than simple LoF (haploinsufficiency) [19].
Second, we demonstrate association between p.Arg1231Cys with stroke, thus demonstrating that
CADASIL-related stroke is not uncommon as was previously thought. While prior studies have
shown enrichment of p.Arg1231Cys in South Asians [21], and have used this information as
evidence to classify p.Arg1231Cys variant as "low-risk" [17], the current study provides
evidence contrary to that verdict. Furthermore, we have demonstrated a broader enrichment of
the variant across the region, including multiple West Asian and South Asian populations. Third,
the prior studies demonstrated a brain-wide association with WMH, while the current study
identifies pathology focused in the external capsule and other brain regions known for
CADASIL pathology.
14
CADASIL is characterized by both ischemic and hemorrhagic strokes, although the factors that
contribute to the manifestation of one versus the other stroke type awaits further clarification [8].
Hemorrhagic stroke appears to represent a larger proportion of strokes in South Asia than in
Europe [2]. In this study, the p.Arg1231Cys association signal was stronger in PGR for
hemorrhagic strokes than for ischemic strokes, despite nearly two-fold larger ischemic stroke
case counts. In contrast, the UKB association signal appeared stronger for ischemic stroke,
possibly due to low hemorrhagic stroke case count and thus statistical power in this cohort.
Statistical power issues aside, differences in manifestation of p.Arg1231Cys in South Asians
compared to Europeans may be attributable to differences in risk factors such as age, blood
pressure, diabetes, air pollution, smoking, medications such as anti-platelet and anti-coagulants
used to manage atherosclerotic disease, genetic background, or study-specific differences in
criteria to categorize stroke sub-types. Further research is needed to better ascertain the
mechanism behind cerebral arterial wall pathobiology and clinical presentation of ischemic
versus hemorrhagic stroke in p.Arg1231Cys carriers.
29
Currently there are no known effective preventive or therapeutic interventions for CADASIL or
less penetrant forms of *NOTCH3* related stroke. However, our analyses provide clues toward
their development. First, in contrast to our analyses of EGFr domain Cys-altering missense
variants in *NOTCH3* that were significantly associated with stroke, predicted loss of function
variants that would be expected to not produce a functional protein were not significantly
associated with stroke. These observations suggest that targeting therapeutic interventions that
decrease expression of mutant protein (such as siRNA, antisense oligonucleotides, and CRISPR),
induce exon skipping of altered EGFr domains [22, 23], or accelerate removal of GOM may
prove beneficial for prevention and/or treatment [24].
39
Our analyses also suggest that p.Arg1231Cys is modestly associated with hypertension, although
p.Arg1231Cys association with stroke risk appears independent of hypertension or other stroke
risk factors such as smoking, age and sex. Animal models of CADASIL show decreased vascular
tone and contractility, most likely driven by loss of physiologic function and subsequent
degeneration of vascular smooth muscle cells (VSMCs) [25]. These observations suggest that
while management of hypertension and smoking cessation are effective modalities for primary
and secondary prevention of stroke, those with *NOTCH3* mutation related strokes will need

additional therapeutic interventions, as existing hypertensive medications cannot restore VSMC
function.
3
A limitation of this study is the lack of brain imaging analysis for the Pakistani carriers, such that
specific brain regions affected by the ischemic and hemorrhagic strokes could be ascertained and
compared. In addition, we lacked more detailed clinical data such as presence of migraines and
longitudinal data of disease course including stroke recurrence, dementia, and depression.
Further characterization of p.Arg1231Cys carriers will be necessary to obtain better estimates of
penetrance as well as to identify distinguishing clinical or biomarker characteristics that may
have utility in early diagnosis, prevention and treatment, and for recommendations for cascade
screening in family members. Migraine symptoms typically precede stroke by 10+ years in
CADASIL patients [8], thus the combination of migraine with aura, depression and family
history of stroke could be sufficient evidence to prescribe *NOTCH3* genetic testing. Finally, the
effect of LoFs on stroke risk will require larger sample sizes for more definitive comparison to
stroke risk of Cys-altering variants.
16
In conclusion, we identified a highly enriched Cys-altering variant in *NOTCH3* in South Asians
that expands the phenotypic spectrum of CADASIL from rare and highly penetrant to common
and moderately penetrant. Based on our estimates, this single variant may be responsible for
~1.0% of all strokes combined and ~5.5% of hemorrhagic strokes in South Asians. Among 1.9
billion South Asians there could be over 26 million carriers for the variant. Thus, this work has
important implications for genetic screening and early identification of at-risk individuals, and
the future opportunity for rationally targeted therapeutic interventions.
24
25   **Online Methods**
26
Details of methods are available in the Supplementary text. Briefly, 75 K individuals were
recruited and consented in Pakistan for exome sequencing, including a stroke case:control
discovery cohort of 31 K (5,135 cases and 26,602 controls) sequenced by the Regeneron
Genetics Center and a follow-up cohort of 44 K, including 30 K with self-report stroke
case:control status used for replication and meta-analysis (160 cases and 30,239 controls).
ExWAS was conducted for stroke and 4 overlapping stroke subtypes (intracerebral hemorrhage,
subcortical intracerebral hemorrhage, ischemic stroke, and partial anterior circulating infarct) in
the discovery cohort and combined in a meta-analysis of stroke with the replication cohort using
both single-variant and gene burden test models [26]. Population attributable fraction of stroke
for associated variants was calculated as described previously [27]. Consented callbacks were
conducted in families of homozygotes for associated variants. For comparison and validation,
analyses were conducted in UK Biobank data as described previously [28-31], including
association analysis of p.Arg1231Cys *NOTCH3* with stroke phenotypes in 380 K participants,
and brain imaging phenotypes in 35 K participants (**Supplementary Methods**; **Figure 1A**).
41
42 **Custom Burden Tests in UKB 450 K**
43
Burden tests aim to boost statistical power by aggregating association signal across multiple rare
variants. Prior studies in human and animal models have debated the role of various variant
classes on *NOTCH3* function, CADASIL pathology and patient prognosis, including experiments

designed to determine if the pathogenicity of CADASIL variants follows a loss of function (LoF)
mechanism [8, 25, 32]. Using data from hundreds of missense and LoF variants in *NOTCH3*
observed in 450 K UKB participant exomes, burden tests were conducted to assess the impact of
LoF and missense variants. We first assessed the impact of Cys-altering variants in EGFr
domains 1 to 34, 1 to 6, and 7 to 34 on stroke risk. To compare the effect of other missense
variants in these same domains, we further tested the effect of Ser-altering variants. Finally, we
tested across the full protein-coding region for association with stroke of (i) LoFs and (ii) LoFs
and missense variants.
Figure Legends
10
Figure 1. ExWAS Identifies *NOTCH3* p.Arg1231Cys Associated with Subcortical
Hemorrhagic Stroke in Pakistan Genome Resource 31 K Discovery Cohort. A. Flow chart
of the study described in this report. The discovery cohort consisted of a 31 K stroke case-control
cohort from the Pakistan Genome Resource (PGR). A second PGR follow-up cohort of 44 K
included 30 K participants with self-reported stroke case:control status for replication. UK
Biobank data from 450 K sequenced participants was used for further analysis in a
predominantly European ancestry population, 380 K of whom had stroke case:control status
known, and 35 K of whom had brain MRI data (see Methods and Supplementary Methods). **B.**
Manhattan plot of subcortical hemorrhagic stroke ExWAS in 31 K PGR discovery cohort
participants with $-\log_{10}$ p-values (y-axis) across chromosomes and variants (x-axis). A single
variant (NC_000019.10:g.15179052G>A) on chromosome 19 predicting a missense variant
p.Arg1231Cys in *NOTCH3* exceeded the genome-wide significance threshold of 5×10^{-8} (red
line). **C.** *NOTCH3* locus zoom plot of subcortical stroke ExWAS. The $-\log_{10}$ p-values for
variants tested are shown on the y-axis. The p.Arg1231Cys variant is labeled as a diamond.
Other variants (circles) are colored based on linkage disequilibrium with the reference variant in
1000 Genomes [33]. Gene exon (thick line) and intron (thin line) model shown below the graph.
27
28

Figure 2. *NOTCH3* EGFR Domain Disruption by p.Arg1231Cys. Shown is *NOTCH3*
p.Arg1231 in context of human *NOTCH3* protein domains and cross-species alignment of
NOTCH3 amino acid sequences. **A.** Human *NOTCH3* Protein Domains. Shown is the position of
the associated variant in context of transcript exons (top, alternating blue and purple with
numbering) and protein domains (bottom, color coded). *NOTCH3* can be divided into four major
regions, from left-to-right the signal peptide (light blue), the extra-cellular domain (ECD,
brown), the transmembrane domain (orange), and the intra-cellular domain (ICD, blue). The
majority of the ECD is composed of 34 Epidermal Growth Factor-like repeat (EGFr) domains (in
purple with white numbers). Domains involved in signaling are highlighted, including EGFr
domains 10 to 11 involved in ligand binding (light purple, numbered), three cleavage domains
(S1 in yellow, S2 in yellow with diagonal black stripes, S3 in yellow with black horizontal
stripes), and three *Lin12*/*NOTCH* repeats (light green, numbered). The ICD contains the
Recombination signal-binding protein for Ig of κ region (RAM) domain for transcription factor
interaction (green and white checkers), the Nuclear Localization Sequences (NLS, orange with
black stripes), five Ankyrin repeats involved in signal transduction (green with white numbers),
and the Proline, glutamic acid, serine, and threonine-rich (PEST) domain essential for
degradation (green with white stripes). The p.Arg1231Cys variant (red line top to bottom)
removes a disulfide-bridge-forming cysteine in the 31st EGFr domain of the ECD, coded by the
22nd exon. **B.** Cross-species Alignment of *NOTCH3* (EGFr) Domain # 31 Amino Acid
Sequences. Shown is an amino acid alignment of 31st EGFr domain of *NOTCH3* (human
sequence amino acids 1205 to 1244), including (top-to-bottom) human reference, human
p.Arg1231Cys mutant, chimpanzee (*Pan troglodytes*), mouse (*Mus musculus*), zebrafish (*Danio
rerio*), western clawed frog (*Xenopus tropicalis*), and green sea turtle (*Chelonia mvdas*),
indicating conservation of the arginine (R) at position 1231 in mammals. Highly-conserved
cysteine (C) residues (normally 6 per EGFR) are highlighted in yellow.
26
27

Figure 3. Forest Plot Showing Replication of *NOTCH3* p.Arg1231Cys Association with
Stroke Across 61 K Pakistan Genome Resource Meta-Analysis. Shown is the cohort name,
trait, odds ratio with 95% confidence interval, p value, alternate allele frequency, case count, and
control count for five stroke phenotypes in the PGR 31 K discovery cohort (top), and Inverse
Variance Weighted (IVW) Meta-Analysis of stroke in 61 K PGR Cohort, including 31 K PGR
discovery cohort and 30 K PGR replication cohort subset of the 44 K PGR follow-up cohort
(bottom).
8
9

1 **Tables**

3 **Table 1. Baseline Characteristics of PGR Stroke Case-control Discovery Cohort[1]**

	Case (n = 5,135)		Control (n = 26,602)			Case p.Arg1231Cys Carrier (n=103)[3]		Case Non-Carrier (n=4,998)		
	mean / n	SD / %	mean / n	SD / %	P value	mean / n	SD / %	mean / n	SD / %	P value
Female, n (%)	2,277	44.3	9,330	35.1	< 0.01	50	48.5	2,211	44.2	0.44
Age at enrolment, years	58.9	13.1	52.8	11.4	< 0.01	58.7	12.1	58.9	13.2	0.87
BMI, kg/m^2	25	3.9	27.5	4.4	< 0.01	24.6	3.4	24.9	3.9	0.35
Cholesterol mg/dL	175.3	55.5	172.1	48.2	< 0.01	174.8	49.1	175.3	55.7	0.94
LDL-C mg/dL	111.1	45.8	101.2	38.2	< 0.01	110.8	41.1	111.1	45.9	0.94
HDL-C mg/dL	37.8	12.7	35	10.8	< 0.01	38.8	12.1	37.8	12.7	0.43
Triglyceride mg/dL	140.3	81.8	185.7	120.1	< 0.01	126.3	62.7	140.5	82.3	0.04
Glucose, mg/dL	148.7	75.5	143.4	84.9	< 0.01	145.2	74.7	148.6	75.3	0.68
HbA1c %	6.9	1.8	6.6	2	< 0.01	7.3	1.9	6.9	1.9	0.15
Creatinine mg/dl	1.2	0.8	0.9	0.5	< 0.01	1.1	0.7	1.2	0.8	0.39
Tobacco or other stimulant user[2]	1,850	36	9,242	34.7	< 0.01	32	31.1	0	0	0.34
Comorbidities										
Hypertension , n (%)	2,953	57.5	9,385	35.3	< 0.01	57	55.3	2,879	57.6	1
Diabetes, n (%)	1,195	23.3	5,766	21.7	< 0.01	29	28.2	1,157	23.1	0.29
Myocardial infarction, n (%)	371	6.2	622	2.3	< 0.01	5	4.9	215	4.3	0.98
Family history of										
Stroke, n (%)	324	6.3	0	0	< 0.01	14	13.6	306	6.1	< 0.01
Hypertension, n (%)	573	11.2	4,299	16.2	< 0.01	15	14.6	556	11.1	0.35
Diabetes, n (%)	349	6.8	5,199	19.5	< 0.01	11	10.7	334	6.7	0.16
Sudden death, n (%)	150	2.9	569	2.1	< 0.01	8	7.8	142	2.8	< 0.01

[1.] Shown are mean or total n and standard deviation or percentage for cases versus controls on
the left and case p.Arg1231Cys *NOTCH3* carriers versus case non-carriers on the right.
Comparison was conducted and p values are shown from chi-square test for categorical
variables (Fisher's exact test if cell size was <5) and from T-test for continuous variables.
[2.] Tobacco or other stimulants include cigarettes, paan (chewed betel leaf and areca nut),
naswar (snuff), gutka (chewing tobacco), huqqa (water pipe), chillum (hasish pipe).
[3.] Genotypes for the p.Arg1231Cys variant were not available for n=34.
13

1
2   **Table 2. UKB Ischemic Stroke Association Across *NOTCH3* Variant Classes and Domains[1]**
3

NOTCH3 Variant Class	Effect [OR (95%CI)]	P value	AAF (%)	Cases (RR|RA|AA)	Controls (RR|RA|AA)
p.Arg1231Cys	3.38 (1.65,6.94)	8.8×10^{-4}	0.02	9124|11|0	370986|139|0
EGFr 1-34 Cys-altering	2.86 (2.14,3.82)	6.3×10^{-10}	0.01	9094|49|0	370693|709|1
EGFr 1-6 Cys-altering	29.51 (10.39,83.82)	1.4×10^{-7}	0.002	9137|6|0	371394|9|0
EGFr 7-34 Cys-altering	2.55 (1.87,3.46)	1.6×10^{-7}	0.098	9100|43|0	370702|700|1
Non-EGFr Cys-altering	0.97 (0.46,2.03)	9.3×10^{-1}	0.039	9136|7|0	371111|292|0
EGFr 1-34 Ser-altering	0.98 (0.8,1.2)	8.4×10^{-1}	0.54	9046|97|0	367355|4042|6
EGFr 1-6 Ser-altering	0.76 (0.23,2.56)	6.6×10^{-1}	0.018	9141|2|0	371271|132|0
EGFr 7-34 Ser-altering	0.99 (0.8,1.21)	8.9×10^{-1}	0.53	9048|95|0	367486|3911|6
Non-EGFr Ser-altering	0.84 (0.52,1.34)	4.5×10^{-1}	0.10	9128|15|0	370656|744|3
LoF variants	1.38 (0.50,3.85)	5.4×10^{-1}	0.019	9138|5|0	371261|142|0
LoF + any missense	1.09 (1.01,1.19)	3.3×10^{-2}	3.30	8490|652|1	346648|24710|45

4
[1.] Burden test with age, age^2, gender, 10 PCs as covariates was conducted using REGENIE to
compare the association signal and effect size across variant classes and domains for
ischemic stroke in 9,143 cases and 371,403 controls from UK Biobank. *NOTCH3* variant
classes include the single variant association (p.Arg1231Cys) for reference at the top and
burden tests limited to: Cys-altering variants in EGFr domains 1 to 34; Cys-altering variants
in EGFr domains 1 to 6; Cys-altering variants in EGFr domains 7 to 34; Cys-altering variants
outside of EGFr domains; Ser-altering variants in EGFr domains 1 to 6; Ser-altering variants
in EGFr domains 7 to 34; Ser-altering variants outside of EGFr domains; Loss of function
(LoF) variants (defined as stop-gain, stop-loss, frameshift and splice-site variants with AAF
<1%); and LoF and any missense variants (AAF < 1%). Abbreviations: EGFr, epidermal
growth factor-like repeat domain; AAF, alternate allele frequency; RR, reference allele
homozygote; RA, reference/alternate allele heterozygote; AA, alternate allele homozygote;
95% CI, 95% confidence interval
18

References

1.   Mills, M.C. and C. Rahal, *The GWAS Diversity Monitor tracks diversity by disease in real time.* Nat Genet, 2020. **52**(3): p. 242-243.

2.   Collaborators, G.B.D.S., *Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.* Lancet Neurol, 2021. **20**(10): p. 795-820.

3.   Sherin, A., et al., *Prevalence of stroke in Pakistan: Findings from Khyber Pakhtunkhwa integrated population health survey (KP-IPHS) 2016-17.* Pak J Med Sci, 2020. **36**(7): p. 1435-1440.

4.   Valcarcel-Nazco, C., et al., *Variability in the use of neuroimaging techniques for diagnosis and follow-up of stroke patients.* Neurologia (Engl Ed), 2019. **34**(6): p. 360-366.

5.   Farooq, A., N. Venketasubramanian, and M. Wasay, *Stroke Care in Pakistan.* Cerebrovasc Dis Extra, 2021. **11**(3): p. 118-121.

6.   Farooq, M.U., et al., *The epidemiology of stroke in Pakistan: past, present, and future.* Int J Stroke, 2009. **4**(5): p. 381-9.

7.   Mullen, M.T., et al., *Hospital-Level Variability in Reporting of Ischemic Stroke Subtypes and Supporting Diagnostic Evaluation in GWTG-Stroke Registry.* J Am Heart Assoc, 2023. **12**(24): p. e031303.

8.   Chabriat, H., et al., *Cadasil.* Lancet Neurol, 2009. **8**(7): p. 643-53.

9.   Markidan, J., et al., *Smoking and Risk of Ischemic Stroke in Young Men.* Stroke, 2018. **49**(5): p. 1276-1278.

10.   Mishra, A., et al., *Stroke genetics informs drug discovery and risk prediction across ancestries.* Nature, 2022. **611**(7934): p. 115-123.

11.   Scott, E.M., et al., *Characterization of Greater Middle Eastern genetic variation for enhanced disease gene discovery.* Nat Genet, 2016. **48**(9): p. 1071-6.

12.   Wang, T., M. Baron, and D. Trump, *An overview of Notch3 function in vascular smooth muscle cells.* Prog Biophys Mol Biol, 2008. **96**(1-3): p. 499-509.

13.   Duvaud, S., et al., *Expasy, the Swiss Bioinformatics Resource Portal, as designed by its users.* Nucleic Acids Res, 2021. **49**(W1): p. W216-w227.

14.   Rutten, J.W., et al., *Broad phenotype of cysteine-altering NOTCH3 variants in UK Biobank: CADASIL to nonpenetrance.* Neurology, 2020. **95**(13): p. e1835-e1843.

15.   Rodriguez-Flores, J.L., et al., *The QChip1 knowledgebase and microarray for precision medicine in Qatar.* NPJ Genom Med, 2022. **7**(1): p. 3.

16.   Hoffmann, T.J., et al., *Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation.* Nat Genet, 2017. **49**(1): p. 54-64.

17.   Hack, R.J., et al., *Three-tiered EGFr domain risk stratification for individualized NOTCH3-small vessel disease prediction.* Brain, 2023. **146**(7): p. 2913-2927.

18.   Cho, B.P.H., et al., *Association of Vascular Risk Factors and Genetic Factors With Penetrance of Variants Causing Monogenic Stroke.* JAMA Neurol, 2022. **79**(12): p. 1303-1311.

19.   Rutten, J.W., et al., *The effect of NOTCH3 pathogenic variant position on CADASIL disease severity: NOTCH3 EGFr 1-6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFr 7-34 pathogenic variant.* Genet Med, 2019. **21**(3): p. 676-682.

20.   ClinVar, N.C.f.B.I.
21.   Rutten, J.W., et al., *Archetypal NOTCH3 mutations frequent in public exome:*
implications for CADASIL. Ann Clin Transl Neurol, 2016. **3**(11): p. 844-853.
22.   Rutten, J.W., et al., *Therapeutic NOTCH3 cysteine correction in CADASIL using exon*
skipping: in vitro proof of concept. Brain, 2016. **139**(Pt 4): p. 1123-35.
23.   Gravesteijn, G., et al., *Naturally occurring NOTCH3 exon skipping attenuates NOTCH3*
protein aggregation and disease severity in CADASIL patients. Hum Mol Genet, 2020.
29(11): p. 1853-1863.
24.   Ghezali, L., et al., *Notch3(ECD) immunotherapy improves cerebrovascular responses in*
CADASIL mice. Ann Neurol, 2018. **84**(2): p. 246-259.
25.   Belin de Chantemele, E.J., et al., *Notch3 is a major regulator of vascular tone in cerebral*
and tail resistance arteries. Arterioscler Thromb Vasc Biol, 2008. **28**(12): p. 2216-24.
26.   Mbatchou, J., et al., *Computationally efficient whole-genome regression for quantitative*
and binary traits. Nat Genet, 2021. **53**(7): p. 1097-1103.
27.   Greenland, S., *Applications of Stratified Analysis Methods*, in *Modern epidemiology:*
Third edition. 2008, Lippincott Williams & Wilkins: Philadelphia. p. 295-297.
28.   Backman, J.D., et al., *Exome sequencing and analysis of 454,787 UK Biobank*
participants. Nature, 2021. **599**(7886): p. 628-634.
29.   Benjamini, Y. and Y. Hochberg, *Controlling the False Discovery Rate: A Practical and*
Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B
(Methodological) 1995. **57**(1): p. 289-300.
30.   Elliott, L.T., et al., *Genome-wide association studies of brain imaging phenotypes in UK*
Biobank. Nature, 2018. **562**(7726): p. 210-216.
31.   Griffanti, L., et al., *BIANCA (Brain Intensity AbNormality Classification Algorithm): A*
new tool for automated segmentation of white matter hyperintensities. Neuroimage, 2016.
141: p. 191-205.
32.   Joutel, A., et al., *Cerebrovascular dysfunction and microcirculation rarefaction precede*
white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease.
J Clin Invest, 2010. **120**(2): p. 433-45.
33.   Genomes Project, C., et al., *A global reference for human genetic variation.* Nature,
2015. **526**(7571): p. 68-74.
32
33
34

Acknowledgements

Supported by Regeneron Pharmaceuticals.

The Institutional Review Board (IRB) at the Center for Non-Communicable Diseases (IRB: 00007048, IORG0005843, FWAS00014490) approved the study. All participants gave written informed consent.

This research has been conducted using the UK Biobank Resource (project 26041). The authors thank everyone who made this work possible, particularly the UK Biobank team, their funders, the professionals from the member institutions who contributed to and supported this work, and most especially the UK Biobank participants, without whom this research would not be possible. The exome sequencing was funded by the UK Biobank Exome Sequencing Consortium (Bristol Myers Squibb, Regeneron, Biogen, Takeda, Abbvie, Alnylam, AstraZeneca and Pfizer). Ethical approval for the UK Biobank was previously obtained from the North West Centre for Research Ethics Committee (11/NW/0382).

Disclosure forms provided by the authors are available with the full text of this article.

Drs. Rodriguez-Flores, Khalid, Shuldiner and Saleheen contributed equally to this article.

1 **Data Sharing**

3   Data used in this manuscript not already available online can be requested from the authors.

1 **Code Sharing**
2
3   Code used to produce data presented in this manuscript not already available online can be
4   requested from the authors.

1   **Primary Individual Contributions**
2

CONCEPTUALIZATION	INVESTIGATION	VALIDATION
Juan L. Rodriguez-Flores (JLRF)	Silvio Alessandro DiGioia (SADG)	Regeneron Genetics Center
Shareef Khalid (SK)	Hector Martinez (HM)	Shareef Khalid
Alan R. Shuldiner (ARS)	I-Chun Tsai (IT)	Juan L. Rodriguez-Flores
Danish Saleheen (DS)	Katia Karalis (KK)	
	Aris Economides (AE)	VISUALIZATION
DATA CURATION	David D'Ambrosio (DDA)	Juan L. Rodriguez-Flores
Nilanjana Banerjee (NB)	Asif Rasheed (AR)	Neelroop Parikshak
Deepika Sharma (DeS)		Farshid Sepehrband
Michael Cantor (MC)	METHODOLOGY	Jonathan Marchini
John Overton (JO)	Juan L. Rodriguez-Flores	Regeneron Genetics Center
Jeff Reid (JR)	Shareef Khalid	
	Regeneron Genetics Center	
FORMAL ANALYSIS		WRITING - ORIGINAL DRAFT
Bin Ye (BY)	PROJECT ADMINISTRATION	Sergio Fazio (SF)
Manav Kapoor (MK)	Thomas Coleman (TC)	Wolfgang Liedtke (WL)
Joshua Backman (JB)	Regeneron Genetics Center	John Danesh (JD)
Gannie Tzoneva (GT)	Asif Rasheed	Ayeesha Kamal (AK)
Ellen Tsai (ET)		Philippe Frossard (PF)
Sahar Gelfman (SG)	RESOURCES	
Tanima De (TD)	Muhammad Jahanzaib (MJ)	WRITING - REVIEW AND
Niek Verweij (NV)	Maleeha Zaman (MZ)	EDITING
Luca A. Lotta (LAL)	Muhammad Rehan Mian (MRM)	
Aaron Zhang (AZ)	Muhammad Bilal Liaqat (MBL)	
Neelroop Parikshak (NP)	Khalid Mahmood (KM)	
Farshid Sepehrband (FS)	Tanvir-us-Salam (TUS)	
Jonathan Marchini (JM)	Muhammad Hussain (MH)	
Giovanni Coppola (GC)	Ayeesha Kamal (AK)	
Sofia Castaneda (SC)	Javed Iqbal (JI)	
Pengcheng Xun (PX)	Faizan Aslam (FA)	
Regeneron Genetics Center		
(RGC)	SOFTWARE	
	Regeneron Genetics Center	
FUNDING AQUISITION	Juan L. Rodriguez-Flores	
Danish Saleheen	Shareef Khalid	
Alan R. Shuldiner		
Aris Baras (AB)	SUPERVISION	
Regeneron Genetics Center	Danish Saleheen	
	Alan R. Shuldiner	

3
4

Competing Interests

Funding

Fieldwork for this study was funded by the Center for Non-Communicable Diseases, Pakistan.

DNA sequencing was funded by Regeneron Pharmaceuticals Inc.

Employment

JLRF, ARS, NB, DeS, MC, JO, JR, BY, MK, JB, GT, SG, TD, NV, LAL, AZ, NP, FS, JM, GC,

PX, AB, SADG, HM, IT, KK, AE, DDA, SF, WL, ET, SC, TC are or were employees of

Regeneron Genetics Center LLC or Regeneron Pharmaceuticals Inc. and contributed to this

manuscript as part of their regular duties as salaried employees.

AR, MJ, MZK, MRM, MBL, PF, and DS and SK are employees of the Center for Non-

Communicable Disease and received salaried compensation for their contribution to this

manuscript.

Personal Financial Interests

JLRF, ARS, NB, DeS, MC, JO, JR, BY, MK, JB, GT, SG, TD, NV, LAL, AZ, NP, FS, JM, GC,

PX, AB, SADG, HM, IT, KK, AE, DDA, SF, WL, TC are or were employees of Regeneron

Genetics Center LLC or Regeneron Pharmaceuticals Inc. and received stock and stock options as

part of their compensation as employees.

JLRF, ARS, DS, AB, and SK are named inventors on patent pending US 20230000897A1 that

discloses methods of treating subjects having a cerebrovascular disease by administering

Neurogenic Locus Notch Homolog Protein 3 (*NOTCH3*) agents, and methods of identifying

subjects having an increased risk of developing a cerebrovascular disease.

A.

Pakistan Genome Resource
75 K

Stroke ExWAS Discovery Cohort
31 K

Follow-up Cohort
44 K

Self-Reported Stroke Case:Control Status
30 K

Stroke Meta-Analysis Cohort
61 K

United Kingdom Biobank

Stroke Replication Cohort
380 K

Brain Imaging Cohort
35 K

B.

NOTCH3

C.

p.Arg1231Cys

←*NOTCH3*

←*MIR6795*

Figure 1

A.

Genome Variants

Chr19:g.15179052G>A

Transcript Exons

NM_000435.3:c.3691C>T

Protein Domains

NOTCH3:p.Arg1231Cys

Protein Coordinates

- ▨ Signal Peptide ▨ Extracellular ▨ Transmembrane ▨ Intracellular ▨ S1 Cleavage ▨ S2 Cleavage ▨ S3 Cleavage ▨ Heterodimer (HD)
- ▨ Epidermal Growth Factor-like repeat (EGFr) ▨ Ligand-Binding EGFr ▨ Lin12/*NOTCH* Repeat (LNR)
- ▨ Recombination signal-binding protein for Ig of κ region (RAM) ▨ Ankyrin Repeat (ANK)
- ▨ Nuclear Localization Sequence (NLS) ▨ Proline, glutamic acid, serine, and threonine-rich (PEST)

B.

	1205		1231		1244	

INECRSGACHAAHTRDCLQDPGGGFRCLCHAGFSGPRCQT **Human 1231 Arg (reference)**

INECRSGACHAAHTRDCLQDPGGGFCCLCHAGFSGPRCQT **Human 1231 Cys (mutant)**

INECRSGACHAAHTRDCLQDPGGGFRCLCHAGFSGPRCQT **Chimpanzee**

INECRPGACHAAHTRDCLQDPGGHFRCVCHPGFTGPRCQI **Mouse**

INECLSNPCNPSNSLDCIQLPND-YQCVCKPGFTGRGCQS **Zebrafish**

INECLSGPCHAQNTRHCVQLAND-YQCVCKSGYTGRRCQS **Western clawed frog**

INECLAKPCLPQRTLDCVQGAND-FQCLCKPGYTGRRCQN **Green sea turtle**

Figure 2

Cohort	Trait	OR (95% CI)	P value	AAF	Cases (RR|RA|AA)	Controls (RR|RA|AA)
	Stroke		4.92E-08	6.13E-03	4939|98|3	25619|271|2
	Ischemic stroke		2.49E-03	5.64E-03	2540|42|2	25619|271|2
Discovery	Intracerebral hemorrhage		1.79E-08	5.82E-03	1451|44|0	25619|271|2
	Subcortical intracerebral hemorrhage		3.87E-09	5.84E-03	1313|43|0	25619|271|2
	Partial anterior circulation infarcts		4.84E-03	5.56E-03	1227|25|1	25619|271|2

0 1 2 3 4 5 6

Cohort	Trait	OR (95% CI)	P value	AAF	Cases	Controls
Discovery	Stroke		4.92E-08	6.13E-03	4939|98|3	25619|271|2
Replication	Stroke		5.00E-03	0.00513	154|6|0	29935|302|2
IVW Meta-Analysis	Stroke		7.79E-10	0.00576	5093|104|3	55617|586|4

0 1 2 3 4 5 6 7 8

Figure 3